Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biological marker for diagnosing and treating liver cancer

A technology for liver cancer and liver cancer treatment, applied in the field of biomarkers, can solve problems such as functions and mechanisms of action that need to be further explored, and achieve the effect of improving accuracy

Active Publication Date: 2017-06-13
TAIZHOU MUNICIPAL HOSPITAL
View PDF5 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the research on lncRNA has made progress in recent years, its function and mechanism of action still need to be further explored.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological marker for diagnosing and treating liver cancer
  • Biological marker for diagnosing and treating liver cancer
  • Biological marker for diagnosing and treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Screening Gene Markers Related to Liver Cancer

[0063] 1. Sample collection

[0064] The cancer tissues and paracancerous tissues of 10 patients with liver cancer were collected, and the patients gave informed consent. All the above specimens were obtained with the consent of the organizational ethics committee.

[0065] 2. Preparation of RNA samples

[0066] Tissue RNA was extracted using QIAGEN tissue RNA extraction kit, and the operation was performed according to the specific steps in the manual.

[0067] 3. Reverse transcription and labeling

[0068] The mRNA was reverse-transcribed into cDNA using the Low RNA Input Linear Amplification Kit, and the experimental group and the control group were labeled with Cy3, respectively.

[0069] 4. Hybridization

[0070] The gene chip uses Cannes Bio-Human lncRNA Array, and hybridization is performed according to the steps of the chip instruction manual.

[0071] 5. Data processing

[0072] After hybridizatio...

Embodiment 2

[0075] Example 2 QPCR sequencing to verify the differential expression of LINC00511 gene

[0076] 1. Large-scale QPCR verification of the differential expression of the LINC00511 gene. According to the sample collection method in Example 1, 60 samples of liver cancer tissues and 60 samples of paracancerous tissues were collected.

[0077] 2. The RNA extraction steps are the same as in Example 1.

[0078] 3. Reverse transcription:

[0079] Use 25μl reaction system, take 1μg total RNA for each sample as template RNA, and add the following components to PCR tubes: DEPC water, 5× reverse transcription buffer, 10mM dNTP, 0.1mM DTT, 30μM Oligo dT, 200U / μl M-MLV, template RNA. Incubate at 42°C for 1 hour, then centrifuge briefly at 72°C for 10 minutes.

[0080] (3) QPCR amplification test

[0081] Primer design:

[0082] The primer sequence of LINC00511 gene is:

[0083] Forward primer: 5'-GCTCAAGTTCCTGACATAA-3' (SEQ ID NO.4)

[0084] Reverse primer: 5'-GCGTTGTGTTAGGCATTA-3' ...

Embodiment 3

[0094] Example 3 Differential expression of LINC00511 gene in liver cancer cell lines

[0095] 1. Cell culture

[0096] Human liver cancer cell lines HepG2, Huh7 and normal liver cell line HL-7702 were incubated in DMEM containing 10% fetal bovine serum and 1% P / S at 37°C and 5% CO 2 , Cultivated in an incubator with a relative humidity of 90%. Change the medium once every 2-3 days, and use 0.25% EDTA-containing trypsin for routine digestion and passage.

[0097] 2. Extraction of RNA

[0098] 1) Stop the culture when the cells reach 80-90% confluency, digest with 0.25% trypsin and collect the cells in 1.5ml EP tubes, add lm1Trizol to each tube and shake slowly to break the cells, place on ice for 10min.

[0099] 2) Remove protein and DNA: add 0.2ml chloroform to each 1.5ml EP tube, shake for 15s, and place at room temperature for 10min. Centrifuge at 12000rpm for 15min at 4°C.

[0100] The rest of the operation steps are the same as the RNA extraction process from the tis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biological marker for diagnosing and treating liver cancer. Specifically, the marker is LINC00511. According to the biological marker, a condition that differential expression of the LINC00511 is related with occurrence and development of the liver cancer is found for the first time; in patients with the liver cancer, expression of the LINC00511 is regulated up to remind that LINC00511 gene expression intervention possibly becomes a new way for treating the liver cancer. In order to further identify, the expression of the LINC00511 is reduced through an inhibitor and the proliferation of liver cancer cells and the quantity of cell formation colonies can be remarkably reduced.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a biomarker for the diagnosis and treatment of liver cancer, in particular to the biomarker LINC00511. Background technique [0002] Hepatocellular carcinoma (HCC) is the most common disease among malignant liver tumors in adults. Although the treatment techniques for liver cancer continue to improve, such as surgical resection, liver transplantation, and radiotherapy and chemotherapy, the overall 5-year survival rate of liver cancer patients is still not obvious. improve. One of the important reasons for the high mortality rate and poor prognosis of liver cancer is that the molecular mechanism of liver cancer development is still poorly understood. However, with the progress of modern cell and molecular biology, it has been proved that the formation of liver cancer is often accompanied by a series of abnormalities in molecules and signaling pathways. Therefore, exploring the mechanism...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68A61K45/00A61P35/00
CPCA61K45/00C12Q1/6886C12Q2600/136C12Q2600/158C12Q2600/178
Inventor 王冬国陈佳玉
Owner TAIZHOU MUNICIPAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com